Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction

European Thyroid Journal
Satoshi KoyamaHiromi Takeuchi

Abstract

Lenvatinib is an oral multitargeted tyrosine kinase inhibitor that has an anticancer action in patients with differentiated thyroid cancer that is refractory to radioiodine. Knowledge of the efficacy and safety of lenvatinib in patients with anaplastic thyroid cancer (ATC) is limited. Tyrosine kinase inhibitors frequently cause hypothyroidism, but the incidence of hypothyroidism with lenvatinib is unclear. We conducted a retrospective study to investigate the efficacy and safety of lenvatinib in ATC. Five patients with unresectable ATC were enrolled. Lenvatinib 24 mg once daily was administered until disease progression, unmanageable toxicity, withdrawal, or death occurred. We retrospectively analyzed the objective response rate (ORR), time to progression (TTP), overall survival, and safety. Three of the 5 patients (60%) had a partial response, and 5 (40%) had stable disease. The ORR was 60%. Median TTP was 88 days, and overall survival was 165 days. Hypothyroidism was a common treatment-related adverse effect; 4 patients (80%) had hypothyroidism of any grade. These 4 patients had not undergone total thyroidectomy prior to lenvatinib administration, and the other patient had undergone total thyroidectomy. Treatment-related adve...Continue Reading

References

Aug 7, 1999·Langenbeck's Archives of Surgery·C PasslerB Niederle
Feb 9, 2002·Annals of Surgical Oncology·Jean-Pierre E N PierieMark J Ott
Feb 14, 2006·Annals of Surgical Oncology·Chandrakanth Are, Ashok R Shaha
Nov 15, 2006·Annals of Surgical Oncology·Neeltje SteeghsHans Gelderblom
Apr 29, 2008·The Laryngoscope·Ashok R Shaha
Mar 27, 2009·Asian Journal of Surgery·Yasuhiro ItoAkira Miyauchi
Mar 5, 2010·Japanese Journal of Clinical Oncology·Kenji KawadaYuichi Ando
Jul 7, 2010·Endocrine-related Cancer·Maya B Lodish, Constantine A Stratakis
Mar 23, 2011·Expert Review of Anticancer Therapy·Stefan L KojicSam M Wiseman
Nov 2, 2012·Thyroid : Official Journal of the American Thyroid Association·Panayiotis SavvidesScot C Remick
Sep 10, 2014·Cancers·Genevieve HousmanSibaji Sarkar
Feb 12, 2015·The New England Journal of Medicine·Martin SchlumbergerSteven I Sherman
Feb 26, 2015·Gland Surgery·Xavier M KeutgenElectron Kebebew
Mar 17, 2017·Frontiers in Oncology·Makoto TaharaShunji Takahashi

❮ Previous
Next ❯

Citations

Oct 15, 2019·Expert Opinion on Drug Discovery·Rosa Maria ParagliolaSalvatore Maria Corsello
Dec 22, 2019·International Journal of Molecular Sciences·Ole Vincent AnckerDaniela Grimm
Oct 16, 2019·The Oncologist·Zhonglin Hao, Peng Wang
Oct 26, 2018·Molecular Cancer·Shikha SainiBellur S Prabhakar
Mar 14, 2019·Frontiers in Oncology·Ethan J HarrisJochen Lorch
Dec 10, 2020·Thyroid Research·Simone De LeoLaura Fugazzola
Jan 29, 2020·Seminars in Cancer Biology·Nikita PozdeyevRebecca E Schweppe
Feb 12, 2020·The Oncologist·Zhonglin Hao, Peng Wang
Jun 17, 2019·Critical Reviews in Oncology/hematology·Arnaud JanninChristine Do Cao

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Martin SchlumbergerSteven I Sherman
Frontiers in Oncology
Makoto TaharaShunji Takahashi
The New England Journal of Medicine
Martin SchlumbergerSteven I Sherman
© 2022 Meta ULC. All rights reserved